港股異動 | 四川成渝(0107.HK)漲逾4% 預計2021年淨利將增至18.38億元左右
格隆匯1月27日丨四川成渝(0107.HK)漲逾4%,報2.07港元,總市值63億港元;四川成渝(601107.SH)亦漲近6%。四川成渝高速公路公佈,預期公司截至2021年12月31日止年度的股東應占純利將增加至人民幣18.38億元左右,較上年度所錄得的股東應占純利人民幣6.75億元顯著上升。該增長主要源於公司於該年度轉讓控股附屬公司仁壽交投置地有限公司的91%股權,使其非經常性損益大幅增加。此外,上年度同期車輛通行費遭受新型冠狀病毒肺炎疫情的負面影響,該年度同期疫情防控趨於常態化,車輛通行費同比增加。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.